Protein having activity as an angiogenesis modulator
CA 2388673 A1 · Owner: Bayer Corporation · Inventors: Wetzel, Gayle Delmonte; Zolotorev, Alya; Dubois-Stringfellow, Nathalie A.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
BTL.012 is a novel human protein useful for regulating or modulating angiogenesis. BTL.012, or variants thereof may be employed as therapeutics in , diseases such as cancer wound healing, diabetic retinopathies, macular degeneration, and cardiovascular diseases and other diseases or clinical , conditions where angiogenesis is relevant to the causation or treatment of the disease.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed March 30, 2001. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended March 30, 2021.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by March 30, 2023.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.